Table 1.
Characteristics of chronic hepatitis B patients with paired liver biopsies at baseline and week 78 after antiviral therapy.
| Characteristics | Baseline n = 162 patients | Week 78 n = 162 patients | P value |
|---|---|---|---|
| Age, years | 36.0 (29.0, 43.0) | — | — |
| Male gender, n (%) | 126 (77.8) | — | — |
| ALT, U/L | 81.4 (43.0, 147.8) | 25.5 (17.1, 34.7) | <0.001 |
| AST, U/L | 52.0 (36.0, 92.1) | 23.4 (19.0, 30.0) | <0.001 |
| Albumin, g/l | 43.0 (40.0, 46.0) | 45.1 (43.0, 48.0) | <0.001 |
| PTA, % | 85.3 (74.9, 98.2) | 102.5 (92.6, 118.0) | <0.001 |
| INR, ratio | 1.07 (1.00, 1.12) | 0.99 (0.94, 1.03) | <0.001 |
| HBV-DNA, Log IU/ml | 6.80 (5.67, 7.76) | 0 (0, 1.31) | <0.001 |
| Liver stiffness value, Kpa | 10.6 (7.4, 14.6) | 6.6 (5.3, 8.6) | <0.001 |
| Ishak fibrosis stage, n (%) | |||
| 0 | 0 | 3 (1.9) | <0.001 |
| 1 | 5 (3.1) | 12 (7.4) | |
| 2 | 35 (21.6) | 47 (29.0) | |
| 3 | 54 (33.3) | 59 (36.4) | |
| 4 | 43 (26.5) | 23 (14.2) | |
| 5 | 21 (13.0) | 17 (10.5) | |
| 6 | 4 (2.5) | 1 (0.6) | |
| Necroinflammatory score, n (%) | <0.001 | ||
| 0–3 | 15 (9.3) | 68 (42.0) | |
| 4–6 | 68 (42.0) | 91 (56.2) | |
| 7–9 | 52 (32.1) | 3 (1.9) | |
| ≥10 | 27 (16.7) | 0 | |
| *P-I-R score, n (%) | <0.001 | ||
| P | 78 (63.9) | 8 (8) | |
| I | 31 (25.4) | 23 (23) | |
| R | 13 (10.7) | 69 (69) | |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; PTA, prothrombin activity; INR, international normalized ratio of prothrombin time. *P-I-R, predominantly progressive, indeterminate, predominantly regressive, only applicable for Ishak ≥3 so there are different case numbers pre- (n = 122) and post-treatment (n = 100).